替妥木单抗：Graves眼病的新希望
朱宋达, 陈国芳, 徐书杭, 刘超 . 替妥木单抗：Graves眼病的新希望[J]. 内科理论与实践, 2021 , 16(06) : 431 -434 . DOI: 10.16138/j.1673-6087.2021.06.013
| [1] | Bartalena L, Piantanida E, Gallo D, et al. Epidemiology, natural history, risk factors, and prevention of Graves’ orbitopathy[J]. Front Endocrinol (Lausanne), 2020, 11: 615993. |
| [2] | Hodgson NM, Rajaii F. Current understanding of the progression and management of thyroid associated orbitopathy[J]. Ophthalmol Ther, 2020, 9(1): 21-33. |
| [3] | Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy[J]. Thyroid, 2008, 18(3): 333-346. |
| [4] | Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy[J]. Eur Thyroid J, 2016, 5(1): 9-26. |
| [5] | Nicosia L, Reverberi C, Agolli L, et al. Orbital radiotherapy plus concomitant steroids in moderate-to-severe Graves’ ophthalmopathy[J]. Int J Endocrinol Metab, 2019, 17(1): e84427. |
| [6] | Aktaran S, Akarsu E, Erbaigci I, et al. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves’ ophthalmopathy[J]. Int J Clin Pract, 2007, 61(1): 45-51. |
| [7] | Kotwal A, Stan M. Current and future treatments for Graves’ disease and Graves’ ophthalmopathy[J]. Horm Metab Res, 2018, 50(12): 871-886. |
| [8] | Stan MN, Garrity JA, Carranza Leon BG, et al. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy[J]. J Clin Endocrinol Metab, 2015, 100(2): 432-441. |
| [9] | Salvi M, Vannucchi G, Currò N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy[J]. J Clin Endocrinol Metab, 2015, 100(2): 422-431. |
| [10] | Stan MN, Salvi M. Mangement of endocrine disease: rituximab therapy for Graves’ orbitopathy[J]. Eur J Endocrinol, 2017, 176(2): R101-R109. |
| [11] | Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy[J]. Am J Ophthalmol, 2018, 195: 181-190. |
| [12] | Rivera-Grana E, Lin P, Suhler EB, et al. Methotrexate as a corticosteroid-sparing agent for thyroid eye disease[J]. J Clin Exp Ophthalmol, 2015, 6(2): 422. |
| [13] | Taylor PN, Zhang L, Lee RWJ, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy[J]. Nat Rev Endocrinol, 2020, 16(2): 104-116. |
| [14] | Ju Y, Yang J. Teprotumumab for the treatment of thyroid eye disease[J]. Expert Rev Clin Immunol, 2020, 16(8): 739-743. |
| [15] | Rapoport B, McLachlan SM. Reflections on thyroid autoimmunity[J]. Horm Metab Res, 2018, 50(12): 840-852. |
| [16] | Tabasum A, Khan I, Taylor P, et al. Thyroid antibody-negative euthyroid Graves’ ophthalmopathy[J]. Endocrinol Diabetes Metab Case Rep, 2016, 2016: 160008. |
| [17] | Pritchard J, Han R, Horst N, et al. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor I receptor pathway[J]. J Immunol, 2003, 170(12): 6348-6354. |
| [18] | 张荧钗, 徐书杭, 刘超. 胰岛素样生长因子Ⅰ受体及其在Graves眼病中作用研究进展[J]. 中华内分泌代谢杂志, 2020, 36(9): 799-802. |
| [19] | Łacheta D, Miéskiewicz P, Głuszko A, et al. Immunological aspects of Graves’ ophthalmopathy[J]. Biomed Res Int, 2019, 2019: 7453260. |
| [20] | Smith TJ. Thyroid-associated ophthalmopathy: emergence of teprotumumab as a promising medical therapy[J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(1): 101383. |
| [21] | Patel A, Yang H, Douglas RS. A new era in the treatment of thyroid eye disease[J]. Am J Ophthalmol, 2019, 208: 281-288. |
| [22] | Krieger CC, Neumann S, Gershengorn MC. Is there evidence for IGF1R-stimulating abs in Graves’ orbitopathy pathogenesis?[J]. Int J Mol Sci, 2020, 21(18): 6561. |
| [23] | Krieger CC, Boutin A, Jang D, et al. Arrestin-β-1 physically scaffolds TSH and IGF1 receptors to enable crosstalk[J]. Endocrinology, 2019, 160(6): 1468-1479. |
| [24] | Paik JS, Kim SE, Kim JH, et al. Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy[J]. Immunobiology, 2020, 225(2): 151902. |
| [25] | Ju Y, Yang J. Teprotumumab for the treatment of thyroid eye disease[J]. Expert Rev Clin Immunol, 2020, 16(8): 739-743. |
| [26] | Ali F, Chorsiya A, Anjum V, et al. Teprotumumab (tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment[J]. Int Ophthalmol, 2021, 41(4): 1549-1561. |
| [27] | Terwee CB, Gerding MN, Dekker FW, et al. Development of a disease specific quality of life questionnaire for patients with Graves’ ophthalmopathy[J]. Br J Ophthalmol, 1998, 82(7): 773-779. |
| [28] | Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy[J]. N Engl J Med, 2017, 376(18): 1748-1761. |
| [29] | Winn BJ, Kersten RC. Teprotumumab: interpreting the clinical trials in the context of thyroid eye disease pathogenesis and current therapies[J]. Ophthalmology, 2021, 128(11): 1627-1651. |
| [30] | Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease[J]. N Engl J Med, 2020, 382(4): 341-352. |
| [31] | Mishra S, Maurya VK, Kumar S, et al. Clinical management and therapeutic strategies for the thyroid-associated ophthalmopathy[J]. Curr Eye Res, 2020, 45(11): 1325-1341. |
/
| 〈 |
|
〉 |
